These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 403050)

  • 1. Hydralazine slow-release: observations on serum profile and clinical efficacy in man.
    Talseth T; Fauchald P; Pape JF
    Curr Ther Res Clin Exp; 1977 Feb; 21(2):157-68. PubMed ID: 403050
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hydralazine in arterial hypertension. Randomized, double-blind comparison between conventional and slow-release preparations].
    Wulff K; Lenz K; Krogsgaard AR; Holst B
    Ugeskr Laeger; 1980 Jul; 142(29):1862-5. PubMed ID: 6996259
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long-term treatment of essential hypertension with hydralazine and alprenolol].
    Pape JF; Pytte R; Fauchald P
    Tidsskr Nor Laegeforen; 1978 Apr; 98(11):552-5. PubMed ID: 653646
    [No Abstract]   [Full Text] [Related]  

  • 4. [Combination therapy with alprenolol and hydralazine in essential hypertension. A controlled clinical study].
    Pape J
    Tidsskr Nor Laegeforen; 1973 May; 93(15):1139-42. PubMed ID: 4584539
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of alprenolol in combination with hydralazine in essential hypertension. A double-blind, crossover study and a long-term follow-up study.
    Pape J
    Acta Med Scand Suppl; 1974; 554():55-62. PubMed ID: 4593674
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and tolerability of hydralazine, in conventional and slow-release preparations, during long-term treatment of primary hypertension.
    Lins LE; Berglund J; Eliasson K; Wernersson B
    Clin Ther; 1983; 5(3):251-9. PubMed ID: 6850719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydralazine in arterial hypertension. Randomized double-blind comparison of conventional/Slow-Release formulation and of b.i.d./q.i.d. dosage regimens.
    Wulff K; Lenz K; Krogsgaard AR; Holst B
    Acta Med Scand; 1980; 208(1-2):49-54. PubMed ID: 7435247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Slow-release hydralazine in the treatment of essential arterial hypertension].
    Moscovici H; Yasbeck Júnior P; Fadul Neto J
    Arq Bras Cardiol; 1982 Sep; 39(3):197-9. PubMed ID: 7186366
    [No Abstract]   [Full Text] [Related]  

  • 9. Slow-release metoprolol, hydrochlorothiazide and hydralazine in stepwise treatment of essential hypertension.
    Houtzagers JJ; Dols DM; Meems L
    Neth J Med; 1984; 27(8):287-92. PubMed ID: 6504227
    [No Abstract]   [Full Text] [Related]  

  • 10. A long-term study of the antihypertensive effect of alprenolol.
    Comerford MB; Pringle A
    Acta Med Scand Suppl; 1974; 554():15-22. PubMed ID: 4593669
    [No Abstract]   [Full Text] [Related]  

  • 11. Alprenolol in angina pectoris. A comparative study of the tablet form and slow-release formulation.
    Lorentzen F; Jorgensen P; Nielsen E; Nyberg G; Hvidt S
    Med J Aust; 1975 Oct; 2(17):668-73. PubMed ID: 1107769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once daily slow-release hydralazine in hypertension.
    O'Boyle CP; Kelly J; O'Brien ET; O'Malley K
    Ir Med J; 1981 Apr; 74(4):115-6. PubMed ID: 7228629
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of food on the bioavailability of "real" and "apparent" hydralazine from conventional and slow-release preparations.
    Liedholm H; Wåhlin-Boll E; Hanson A; Melander A
    Drug Nutr Interact; 1982; 1(4):293-302. PubMed ID: 6926836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of multiple and combination tablet drug therapy in hypertension.
    David NA; Welborn WS; Pierce HI
    Curr Ther Res Clin Exp; 1975 Dec; 18(6):741-54. PubMed ID: 813939
    [No Abstract]   [Full Text] [Related]  

  • 15. Hydralazine and beta-adrenergic blockade in the treatment of hypertension.
    Siitonen L; Jänne J; Keyriläinen O; Koskinen P; Leskinen O; Pitkäjärvi T; Reinikainen M
    Ann Clin Res; 1974 Dec; 6(6):341-6. PubMed ID: 4155933
    [No Abstract]   [Full Text] [Related]  

  • 16. Relation of hydralazine plasma concentration to dosage and hypotensive action.
    Zacest R; Koch-Weser J
    Clin Pharmacol Ther; 1972; 13(3):420-5. PubMed ID: 5026380
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical administration of hydralazin (Depressan) in essential and renal hypertension].
    Teichmann G; Harms R; Wedler B; Rohmann H
    Z Arztl Fortbild (Jena); 1972 Nov; 66(21):1112-6. PubMed ID: 4576549
    [No Abstract]   [Full Text] [Related]  

  • 18. Reserpine, hydralazine, hydrochlorothiazide combination (Ser-AP-ES) in essential hypertension.
    Glazer N
    Curr Ther Res Clin Exp; 1972 Sep; 14(9):561-72. PubMed ID: 4628678
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydralazine once daily in hypertension.
    Silas JH; Ramsay LE; Freestone S
    Br Med J (Clin Res Ed); 1982 May; 284(6329):1602-4. PubMed ID: 6805621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma renin concentration in essential hypertension during beta-adrenergic blockade and vasodilator therapy.
    Pedersen EB; Kornerup HJ
    Eur J Clin Pharmacol; 1977 Oct; 12(2):93-6. PubMed ID: 923630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.